Burning Rock Biotech (NASDAQ:BNR) Issues Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) posted its earnings results on Thursday. The company reported ($0.21) EPS for the quarter, FiscalAI reports. The business had revenue of $18.05 million during the quarter. Burning Rock Biotech had a negative net margin of 22.33% and a negative return on equity of 21.26%.

Burning Rock Biotech Stock Down 26.0%

BNR stock traded down $5.93 during midday trading on Friday, reaching $16.92. 35,815 shares of the company were exchanged, compared to its average volume of 25,025. The company has a market cap of $182.05 million, a price-to-earnings ratio of -10.19 and a beta of 1.35. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.91 and a current ratio of 3.14. Burning Rock Biotech has a 1-year low of $2.18 and a 1-year high of $41.72. The stock’s 50-day simple moving average is $28.49 and its 200 day simple moving average is $18.44.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Prospera Financial Services Inc acquired a new position in Burning Rock Biotech in the 3rd quarter valued at $214,000. Crcm LP lifted its stake in shares of Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after acquiring an additional 26,809 shares during the period. Marshall Wace LLP purchased a new stake in shares of Burning Rock Biotech in the fourth quarter valued at about $220,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Burning Rock Biotech during the third quarter worth about $26,000. Institutional investors and hedge funds own 30.03% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on BNR. Wall Street Zen raised Burning Rock Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.